Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Capacitación en habilidades de comunicación empática para proveedores de atención del cáncer para ayudar a detener el estigma del cáncer de pulmón que experimentan los pacientes

6 de octubre de 2026 actualizado por: Memorial Sloan Kettering Cancer Center

Capacitación en habilidades de comunicación empática para reducir el estigma del cáncer de pulmón

Research indicates that perceived stigma within medical encounters is prevalent and problematic for lung cancer patients' well-being and quality of cancer care. Promoting empathic communication appears to be a potentially effective intervention target to help reduce patients' perceptions of stigma within clinical encounters; however, no formal trainings exist that focus on teaching empathic communication to oncology care providers (OCPs). Building upon favorable findings from a prior R21 (R21CA202793) and the importance of developing interventions to address lung cancer stigma, our goal is to conduct a national trial of empathic communication skills (ECS) training to facilitate improvements in the medical and psychosocial care of patients through de-stigmatizing interactions with OCPs for patients diagnosed with lung cancer.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

The aims of this study are:

  1. to evaluate the effect of the ECS training on OCP primary outcomes (communication and empathic skill uptake) and secondary outcomes (ECS training appraisal - relevance, novelty, clarity; self-efficacy, empathy, compassion burn-out);

  2. to evaluate the effect of the ECS training vs. WLC on patients' reported primary outcomes (lung cancer stigma), and secondary outcomes (perceived clinician empathy, satisfaction with communication, psychological distress, patients' experience of clinical encounter, and overall patient satisfaction).

    Additionally, acceptance of referral to tobacco cessation (for those currently smoking) will be explored; and

  3. to examine potential moderators of OCP (e.g., demographic characteristics, professional role characteristics) and patient outcomes (e.g., demographic characteristics, illness characteristics).

Our central hypothesis is that the ECS training will demonstrate significant short-term improvements in clinicians' uptake of empathic skills and self-efficacy and will be superior to WLC with regards to patient reported measures of stigma, clinician empathy, satisfaction, and overall experience.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

1232

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Jamie Ostroff, PhD
  • Número de teléfono: 646-888-0041
  • Correo electrónico: ostroffj@mskcc.org

Copia de seguridad de contactos de estudio

  • Nombre: Smita Banerjee, PhD
  • Número de teléfono: 646-888-0011
  • Correo electrónico: banerjes@mskcc.org

Ubicaciones de estudio

    • California
      • Irvine, California, Estados Unidos, 92612
        • Terminado
        • Providence St. Joseph Health (Data Collection Only)
    • Florida
      • Miami, Florida, Estados Unidos, 33143
        • Reclutamiento
        • BAPTIST ALLIANCE - MCI (Data Collection Only)
        • Contacto:
          • Ian Bostock, MD
          • Número de teléfono: 786-596-2000
    • Illinois
      • Libertyville, Illinois, Estados Unidos, 60048
        • Reclutamiento
        • Advocate Health Care Network
        • Contacto:
          • Michael Breen, MD
          • Número de teléfono: 847-367-6781
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536-0093
        • Terminado
        • University of Kentucky (Data Collection Only)
    • Michigan
      • Traverse City, Michigan, Estados Unidos, 49684
        • Terminado
        • Munson Healthcare (Data Collection Only)
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601
        • Reclutamiento
        • Hackensack Meridian Health (Data collection only)
        • Contacto:
          • David Greenberg, MD
          • Número de teléfono: 551-996-8704
    • New York
      • Buffalo, New York, Estados Unidos, 14263-0001
        • Reclutamiento
        • Roswell Park Cancer Institute (Data Collection Only)
        • Contacto:
          • Elisabeth Dexter, MD
          • Número de teléfono: 716-845-2300
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • Contacto:
          • Smita Banerjee, PhD
          • Número de teléfono: 646-888-0011
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19111
        • Reclutamiento
        • Fox Chase Cancer Center (Data Collection Only)
        • Contacto:
          • Linda Fleisher, PhD, MPH
          • Número de teléfono: 215-728-4066
      • Philadelphia, Pennsylvania, Estados Unidos, 19104-4283
        • Reclutamiento
        • University of Pennsylvania (Data Collection Only)
        • Contacto:
          • Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP
          • Número de teléfono: (215) 615-5858
      • Philadelphia, Pennsylvania, Estados Unidos, 08060
        • Terminado
        • Virtua Health (Data Collection Only)
    • Virginia
      • Chesapeake, Virginia, Estados Unidos, 23320
        • Reclutamiento
        • Chesapeake Regional Healthcare (Data Collection Only)
        • Contacto:
          • Stephen Noble, MD
          • Número de teléfono: 757-842-4499

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 100 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Site Eligibility

  • Employs at least 15 FTE OCPs (i.e., oncologists, nurse practitioners and physician assistants) as per self report
  • Reports a clinic volume of at least 20 new lung cancer patients per month as per self report

OCP Participant Eligibility

  • OCPs who are thoracic oncology physicians (radiologists, medical oncologists, pulmonologists, and surgeons), NPs, or PAs and currently treating lung cancer patients, as per self-report;
  • OCP conducts consultations with lung cancer patients, as per self-report;
  • OCP sees at least 1 lung cancer patient per week, as per self-report;

Patient Eligibility

  • Patient under the care of a participating OCP as per self report;

  • English and/or Spanish speaking;

    • In general, which language do you prefer to receive your medical care, English/Spanish/both English and Spanish Equally?
    • If English, treat as fluent in English, no additional language questions
    • If Spanish, treat as fluent in Spanish, no additional language questions
    • If both English and Spanish equally, ask the follow-up questions and go with whichever language is endorsed as best. If endorsed equally, assign to category patient prefers
    • How well do you speak English? Not at all/ Not well/Well/Very well
    • How well do you speak Spanish? Not at all/Not well/Well/Very well
  • Is at least 18 years of age as per self report;

  • Has a history of suspicious lung mass or confirmed lung cancer diagnosis, as per clinician judgment or medical record note;

  • Is a former or current smoking as per self report;

  • Has had no more than 10 prior visits with the participating OCP, as per the medical record and/or self report

Exclusion Criteria:

Patient Exclusion

  • Individuals of impaired decision-making capacity as per a clinician's judgment or as documented in the EMR.

Site and OCP Exclusion

  • None

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Oncology Care Providers/OCP-intervention group

Providers participate in Empathic Communication Skills (ECS) training

The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given "small doses" of an opposing viewpoint (termed as "preparing patients for recurring smoking questions") and suggestions of "counterarguments" in order to make them resistant to future stigmatizing attacks by others

Comparador activo: Oncology Care Providers/OCP-control group

Providers complete all study measures and are offered ECS training after data collection is completed at their site.

Standard of Care participant interaction

Experimental: Participants with Lung Cancer-intervention group

Participants will engage with oncology care providers/OCP who have undergone Empathic Communication Skills (ECS) training

The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given "small doses" of an opposing viewpoint (termed as "preparing patients for recurring smoking questions") and suggestions of "counterarguments" in order to make them resistant to future stigmatizing attacks by others

Comparador activo: Participants with Lung Cancer-control group

Waitlist control group - WLC

Standard of Care participant interaction

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Uptake of communication skills using standardized patient assessment/SPAs
Periodo de tiempo: 3 months

A SPA involves a 12-minute video recorded interaction between the Oncology Care Provider/OCP and the Standardized Patient/SP on a given clinical scenario, using standardized scripts by the SP. Each OCP will participate in one SPA prior to their ECS training and one SPA following training or the timed control period. In contrast to clinical consultation recordings with varied clinical situations that do not necessitate the use of all strategies and skills, the semi-structured nature of SPAs permits appraisal of all desired elements of training.

3 months
Uptake of empathy skills using standardized patient assessment/SPAs
Periodo de tiempo: 3 months

A SPA involves a 12-minute video recorded interaction between the Oncology Care Provider/OCP and the Standardized Patient/SP on a given clinical scenario, using standardized scripts by the SP. Each OCP will participate in one SPA prior to their ECS training and one SPA following training or the timed control period. In contrast to clinical consultation recordings with varied clinical situations that do not necessitate the use of all strategies and skills, the semi-structured nature of SPAs permits appraisal of all desired elements of training.

3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Smita Banerjee, PhD, Memorial Sloan Kettering Cancer Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de abril de 2023

Finalización primaria (Estimado)

31 de agosto de 2027

Finalización del estudio (Estimado)

31 de agosto de 2027

Fechas de registro del estudio

Enviado por primera vez

8 de julio de 2022

Primero enviado que cumplió con los criterios de control de calidad

8 de julio de 2022

Publicado por primera vez (Actual)

13 de julio de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

7 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 21-339

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .